The Chromatography Forum

of Delaware Valley

 

 

CFDV Symposium 2025: Advances in Chromatographic Method Development

 

 

SAVE THE DATE: April 17, 2025

 

 

MORE INFORMATION AVAILABLE SOON

 

 

Affiliated Short Course: Systematic HPLC Troubleshooting on April 16, 2025

More information on short course available here.

 

 

Student & Young Professional Poster Session: Click here for the poster program website and for more details on abstract submission.

 

 

Preliminary Speaker List:

 

Mary Ellen McNally - FMC Corporation

Why Choose a Multi-Analyte Method? 

 

In regulatory laboratories, where potentially hundreds of different types of sample and active ingredients can be evaluated every year, a unique set of conditions provided by agricultural product manufacturers in their regulatory methods are faced with the decision to purchase a new and different analytical column or not follow the enforcement method provided by the manufacturer.  Because of this, a multi-analyte method has been developed at the Irish Department of Agriculture, Food and The Marine, contributed to by the regulatory laboratories in Belgium and the Czech Republic, analyzing more than 70 active ingredients using high performance liquid chromatography (HPLC) and more than 35 active ingredients by ultrahigh-pressure liquid chromatography (UHPLC).  The method has been designed for use by quality control laboratories and is suitable for determining a range of active substances in a wider range of formulated products as well as the technical AI itself. The method has been validated for linearity, precision, accuracy, and specificity for seven technical active ingredients as defined by FMC Corporation.  The method and results will be discussed.

 

 

 

Jessica Sampson - University of Delaware

Data Quantity and Quality in High Throughput Synthesis

 

High throughput experimentation (HTE) is a crucial workflow for the collection of large datasets on chemical reactivity, but key to this is robust, flexible, and adaptable analysis. Selection and development of appropriate methods both limits and guides what reactions can be studied and what information about desired and undesired reactivity can be obtained. At the High Throughput Experimentation Center at the University of Delaware, we employ GC, SFC, and reverse phase LC separations to collect datasets for reaction optimization, development, and scope evaluation. This talk will discuss our strategies for increasing the ease and speed of analysis, while ensuring robust and high-quality analysis, through the use of multiple separation and detection modes.

 

 

Jim Edwards - Saint Louis University

Chemical Derivatization with Capillary LC-MS: Method Development for High Sensitivity Metabolomics

 

A major impediment to metabolomics unleashing its full potential is the complexity of the data which is cluttered with impurities. We use chemical tags to react with a variety of metabolites which confer hydrophobicity for improved LC and chargeability to improve MS response. Ultimately these tags increase signal and through sample stacking allow analysis of ultra-small samples. The first set of reagents allows for pre-concentrating all metabolites and minimal degeneracy/salt adduction. The second set of tags are neucode based tags for high resolution mass spectrometry capable of analyzing up to 96 samples simultaneously. The last set of tags are designed to fragments across the carbon-carbon backbone to allow identification of new metabolites using fragmentation modeling. We leverage the increase in sensitivity to analyze single islets of Langerhans. Defects in islet metabolism are linked to impaired insulin secretion and type 2 diabetes.

 

 

Pankaj Aggarwal - Merck

 

 

 

Matthew Swoyer - GSK

Accelerating HPLC method development with in silico modelling

 

Development of an Active Pharmaceutical Ingredient (API) manufacturing process is a cross- departmental effort requiring close collaboration between process chemistry and analytical development scientists. A critical aspect of a quality process is the use of chromatographic methods capable of quantifying all known and unknown impurities at each synthetic step. These impurities have the potential to impact patient safety, process efficiency and scalability, and are therefore essential to control. At GSK, a defined protocol is utilized for chromatographic method development. This protocol is revised as new technologies emerge and become established in the separation science space. In this discussion, the recent incorporation of an in silico modelling software package to the method development protocol will be covered. The introduction of in silico modeling facilitates a reduction in the number of experiments, minimizing both resource expenditure and the environmental footprint of method development activities. Two case studies will be highlighted, exploring the capabilities of this technology in accelerating and improving chromatographic method development. In silico modelling was leveraged to streamline development and swiftly adapt to unforeseen challenges that arose.

 

 

 

 

Exhibiting sponsors are listed below. If you are interested in sponsoring, please click here.

           

      
 

 

 

 

 

 

Speakers